Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Madan Website

Ravi A. Madan, M.D.

Selected Publications

1)  Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 13: 501-8, 2012.
2)  Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA.
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Cancer Immunol. Immunother. 63: 225-34, 2014.
3)  Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Cancer Immunol. Immunother. 59: 663-74, 2010.
4)  Madan RA, Gulley JL, Fojo T, Dahut WL.
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.
Oncologist. 15: 969-75, 2010.
5)  Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM.
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
Clin. Cancer Res. 14: 4526-31, 2008.
6)  Madan RA, Gulley JL, Kantoff PW.
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
Cancer J. 19: 50-8, 2013.
7)  Madan RA, Tsang KY, Bilusic M, Vergati M, Poole DJ, Jochems C, Tucker JA, Schlom J, Giaccone G, Gulley JL.
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
Oncologist. 18: 821-2, 2013.
8)  Singh N, Madan RA, Gulley JL.
Ipilimumab in prostate cancer.
Expert Opin Biol Ther. 13: 303-13, 2013.
9)  Madan RA, Shah AA, Dahut WL.
Is It Time to Reevaluate Definitive Therapy in Prostate Cancer?.
J. Natl. Cancer Inst. [Epub ahead of print], 2013.
10)  Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Cancer Immunol. Immunother. 62: 1521-31, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 7/11/2014.